Incyte Corporation, INCY is in the exchange NASDAQ and its industry is Biotechnology in the sector of Healthcare. Based in USA, Incyte Corporation, INCY has a market cap of 15198.49. Since its IPO date on the 11/4/1993, Incyte Corporation, INCY performance year to date is -25.33%. Today Incyte Corporation, INCY has gained -0.43%, with a current price of 80.98.
Ownership of the company is 0.50% for insider ownership while institutional ownership is 97.20%. The management of the company have seen the company have a payout ratio of 0.00%. Return of assets are at 6.60%, with return on investment at 6.30%.
In terms of debt levels and profit levels, Incyte Corporation, INCY is seeing a long-term debt/equity of 2.14. While Total debt/equity is 0. With a profit margin of 7.90%, this is combined with a gross margin of 96.20%, and operating margin of 15.50%. Incyte Corporation ability to meet debt levels, with a current ratio of 4, while the quick ratio is 4.
For the last year Incyte Corporation, INCY has seen a EPS growth of 112.10%. A performance for the year of -30.30%. The 52-week high is -39.40%, and the 52-week low is 47.24%. The average volume for Incyte Corporation, INCY is 764400.
With a target price of 98.71, can Incyte Corporation, INCY reach this target? Looking at the value indicators of Incyte Corporation, INCY. Incyte Corporation has a P/E of 238.88 and a forward P/E of 59.41. Perhaps the more useful indicator than P/E, is PEG which has a value of 4.31. Incyte Corporation also has a P/S and a P/B of 16.15 and 51.25 respectively. For P/cash, Incyte Corporation has a value of 24.16, while it is 179.23 for P/free cash flow.
At the current price of 80.98, Incyte Corporation has a dividend yield of *TBA. We see a return on equity of 37.80%.
Looking more long-term Incyte Corporation, is projected to get an EPS growth for the next five years of 55.39%. In the short-term an EPS growth of 640.76% in the next year is forecasted. This is after a EPS growth of 112.10% for this year and for the last five years a 16.40% growth has been seen.